ReviewJournal of immunotherapy (Hagerstown, Md. : 1997)
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.
Review in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00683670 (Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma), which is not on this map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma
Who cites it
87 citing papers in PubMed, 206 citations in OpenAlex.
- Trial
- Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.Cellular & molecular immunology · 2015Trial
- Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.Journal of translational medicine · 2011Trial
- A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011Trial
- Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.Journal of cancer research and clinical oncology · 2011Trial
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.Cytotherapy · 2011Trial
- IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.Blood · 2006Trial
- Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.Journal of immunotherapy (Hagerstown, Md. : 1997)Trial
- A Two-way Mendelian randomisation study of inflammatory factors and the risk of meningioma.Translational neuroscience · 2026Article
- Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives.Immuno-oncology technology · 2025Review
- Bridging transplantation and immunotherapy: Clinical promise of autologous stem cell transplantation with chimeric antigen receptor T-cell therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Article
- An updated review of small-molecule HPK1 kinase inhibitors (2016-present).Future medicinal chemistry · 2024Review
- Results of flow cytometric detection of gamma-deltaT cells in peripheral blood of patients with ankylosing spondylitis: a pilot study.Physiological research · 2023Article
- Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?Frontiers in immunology · 2023Review
- Development of Adaptive Immunity and Its Role in Lung Remodeling.Advances in experimental medicine and biology · 2023Article
- Regulatory T cells in inflammation and resolution of acute lung injury.The clinical respiratory journal · 2022Review
- Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics.Heliyon · 2022Review
- Association of the TGFβ gene family with microenvironmental features of gastric cancer and prediction of response to immunotherapy.Frontiers in oncology · 2022Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
CD4+CD25+ T regulatory (Treg) cells control immunologic tolerance to self-antigens and play a role in suppressing antitumor immune responses, but the mechanism of suppression in vivo remains uncertain. Recently, signaling through the high-affinity interleukin-2 (IL-2) receptor has been shown to be critical for Treg cell differentiation and survival in vivo. Mice deficient in IL-2 or its receptor (CD25 or CD122) or deficient in downstream signaling molecules, including JAK-3 and STAT-5, do not develop a stable population of Treg cells and subsequently acquire lymphoproliferative disease and autoimmunity. in vitro, IL-2 is required to expand Treg cells and to induce their suppressive characteristics. Conversely, IL-2-based regimens can activate cellular antitumor immunity and are the mainstay of immunotherapies directed against melanoma and kidney cancers. Given the seemingly disparate effects of IL-2, the authors discuss the possibility that IL-2 may not be the optimal T-cell growth factor in vivo, but rather an inducer of self-tolerance. The authors propose that other gamma c-signaling cytokines, including IL-15, may be alternative choices for the immunotherapy of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.